Company Overview & History
Company Overview
- Name
- Kringle Pharma , Inc.
- Established
- December 21, 2001
- Representative
- President & CEO Kiichi Adachi
- Head Office
- 10F, Nakanoshima Qross Research & Development Center,
4-3-51 Nakanoshima, Kita-ku, Osaka 530-0005, JAPAN
- Business
- R&D, manufacturing, and marketing of HGF-based pharmaceuticals
- Capital
- 64 million yen (as of the end of September 2025)
- Number of Officers
- 7 Board Members, 3 Auditors
- Number of Employees
- 17 (as of the end of September 2025)
- Stock Exchange Listing
- Tokyo Stock Exchange Growth Market
(Securities code: 4884) - Fiscal Year End
- September
Origin of the Company Name
Kringle Pharma, Inc.
“Kringle domain” is the name of the characteristic protein structure found in HGF, which is believed to play a role in binding mediators (e.g., membranes, other proteins or phospholipids), and in the regulation of proteolytic activity. Our company name, Kringle Pharma, is derived from this “Kringle domain” and “Pharmaceutical company.”
Access
- Head Office
-
10F, Nakanoshima Qross Research & Development Center,
4-3-51 Nakanoshima, Kita-ku, Osaka 530-0005, JAPAN - https://www.nakanoshima-qross.jp/en/access/
History
- 2001
-
- December
- Established Kringle Pharma, Inc. in Kita-ku, Osaka
- 2005
-
- May
- Obtained a license to develop and commercialize HGF protein from Toshikazu Nakamura, Professor Emeritus of Osaka University, and began pharmaceutical development (development code: KP-100)
- 2007
-
- June
- Established a manufacturing method for mass production of pharmaceutical-grade HGF protein as an active pharmaceutical ingredient
- 2012
-
- April
- Completed Phase Ib study of HGF protein for renal failure patients in the US
- 2015
-
- March
- Completed Phase I study of HGF protein for ALS patients in Japan
- 2016
-
- November
- Completed investigator-initiated Phase I/II study of HGF protein in patients with vocal fold scar in Japan
- 2018
-
- October
- Completed Phase I/II study of HGF protein in patients with acute phase spinal cord injury in Japan
- 2019
-
- September
- The Ministry of Health, Labour and Welfare designated HGF protein as an orphan drug for the treatment of acute phase spinal cord injury
- 2020
-
- March
- Capital and business alliance with TOHO HOLDINGS CO., LTD. for distribution of HGF-based drugs in Japan in acute phase spinal cord injury
- April
- Signed a license and supply agreement with Claris Biotherapeutics, Inc. (US)
- July
- Initiated Phase III study of KP-100IT in patients with acute phase spinal cord injury in Japan
- August
- Capital and business alliance with Maruishi Pharmaceutical Co., Ltd. to establish a marketing network for KP-100IT for treating acute phase spinal cord injury
- December
- Listed on the Mothers Market (currently Growth Market) of the Tokyo Stock Exchange
- 2021
-
- February
- Signed a joint research agreement with Keio University School of Medicine, aiming to develop an advanced therapy using HGF and other technologies for the treatment of spinal cord injury
- August
- Claris Biotherapeutics, Inc. began Phase I/II study for the treatment of neurotrophic keratitis in the US
- September
- “Oremepermin Alfa” was registered as the International Nonproprietary Name (INN) for recombinant human HGF (Development code: KP-100)
- December
- Patent entitled “HGF preparation suitable for treatment of nervous diseases” granted in Europe
- 2022
-
- March
- Jointly filed a patent application with Keio University School of Medicine for the treatment of chronic spinal cord injury
- September
- Jointly filed a patent application with Keio University School of Medicine for the combination therapy using HGF and iPS cells in spinal cord injury
- November
- Initiated Phase III study of HGF protein in patients with vocal fold scar in Japan
- 2023
-
- September
- Started collaboration with Claris Biotherapeutics, Inc. to increase efficiency and scale up production of recombinant human HGF to meet growing global market demand
- October
- Completion of the last observation day of a phase III study in acute phase spinal cord injury
- 2024
-
- February
- Announced topline data from phase III study of KP-100IT in acute spinal cord injury
- May
- The generic name for HGF in Japan was decided as "Oremepermin Alpha"
- 2025
-
- April
- Opened Nakanoshima Qross Office
- June
- Recombinant HGF protein for the treatment of acute spinal cord injury was granted Orphan Drug Designation in the United States
- October
- Formulated an Action Plan as a General Employer
- November
- Established a U.S. subsidiary (Kringle Pharma USA, Inc.)